US 12,331,019 B2
Modified amino acid derivatives for the treatment of neurological diseases and selected psychiatric disorders
Krzysztof Kaminski, Cracow (PL); Michal Abram, Cracow (PL); Marcin Jakubiec, Wilkowice (PL); Anna Rapacz, Cracow (PL); Szczepan Mogilski, Labowa (PL); Gniewomir Latacz, Wolbrom (PL); and Marta Struga, Milanowek (PL)
Assigned to Uniwersytet Jagiellonski, Cracow (PL); and Warszawski Uniwersytet Medyczny, Cracow (PL)
Filed by Uniwersytet Jagiellonski, Cracow (PL); and Warszawski Uniwersytet Medyczny, Warsaw (PL)
Filed on Sep. 30, 2024, as Appl. No. 18/901,530.
Application 18/901,530 is a division of application No. 17/593,974, previously published as PCT/PL2020/050028, filed on Apr. 16, 2020.
Claims priority of application No. 429656 (PL), filed on Apr. 16, 2019.
Prior Publication US 2025/0026717 A1, Jan. 23, 2025
Int. Cl. C07D 207/27 (2006.01); A61P 25/28 (2006.01); C07D 207/404 (2006.01); C07D 207/416 (2006.01)
CPC C07D 207/27 (2013.01) [A61P 25/28 (2018.01); C07D 207/404 (2013.01); C07D 207/416 (2013.01)] 17 Claims
 
1. A compound of formula (I)

OG Complex Work Unit Chemistry
wherein:
X is hydrogen or N(CH3)2,
Y is CH2 or C═O,
R is hydrogen or halogen,
or pharmaceutically acceptable salts thereof.